Oroxylin A suppresses LL-37-induced rosacea-like skin inflammation by modulating SIRT3-SOD2-NF-κB signaling

Rosacea is a chronic inflammatory skin condition characterized by erythema and papules, often triggered by the antimicrobial peptide LL-37. Current treatments often have limited efficacy or side effects. Understanding the underlying molecular mechanisms, such as the SIRT3-SOD2-NF-κB pathway, offers potential targets for novel therapeutic interventions to mitigate this inflammatory response. This study explores Oroxylin A's role in this context.

Researchers investigated the effects of Oroxylin A on LL-37-induced rosacea-like skin inflammation in an unspecified preclinical model. Inflammatory cytokines, including IL-1β, IL-6, and TNF-α, were quantified using ELISA. Protein expression of TLR2, KLK5, and MMP9 was analyzed via immunohistochemistry. KEGG enrichment analysis was performed to identify key inflammatory pathways, with NF-κB highlighted as a central component.

Oroxylin A suppressed LL-37-generated rosacea-like skin inflammation. IL-1β was identified as a core target in the inflammatory process. KEGG enrichment analysis highlighted inflammatory pathways, including NF-κB, as being modulated. The study indicated that Oroxylin A's suppressive effects were mediated through the modulation of the SIRT3-SOD2-NF-κB signaling pathway. Specific quantitative data on cytokine reduction or protein expression changes were not provided in the available abstract fragments.